|
The present studies attempted to determine, in much greater detail, the molecular mechanisms by which sorafenib and vorinostat, as individual agents, interacted to activate CD95 and promote drug toxicity.Sorafenib caused a dose-dependent increase in CD95 tyrosine phosphorylation and, based on multiple criteria, in parallel activated Src family nonreceptor tyrosine kinases. Expression of dominant negative Src or knockout of Src/Fyn/Yes blocked sorafenib-induced CD95 tyrosine phosphorylation. CD95 (Y232F, Y291F) was not activated by either higher sorafenib (6 µmol/L) concentrations or by sorafenib (3 µmol/L) and vorinostat treatment. Knockdown of class III receptor tyrosine kinase PDGFRß expression enhanced Src activity; in a Src-dependent fashion, knockdown of PDGFRß enhanced CD95 tyrosine phosphorylation and also suppressed the ability of sorafenib to induce CD95 tyrosine phosphorylation. Vorinostat rapidly enhanced the ability of lower sorafenib concentrations to increase ROS levels and to transiently suppress total cellular PTPase activity within 1 hour, which was due to ROS generation. However, ROS generation also significantly enhanced PTPase activity 3 hours after drug treatment and correlated with Src Y527 dephosphorylation and with vorinostat-stimulated CD95 tyrosine phosphorylation. Thus, one potential model for molecular drug action is that sorafenib-mediated inhibition of PDGFRß causes a compensatory activation of Src family tyrosine kinases that in turn phosphorylate and activate CD95. In addition, based on the degree to which PDGFRß is inhibited by sorafenib, CD95 becomes tyrosine-phosphorylated in a Src-dependent fashion. Vorinostat, by interacting with sorafenib to elevate ROS levels, rapidly suppresses cellular PTPase activity which promotes greater levels of CD95 tyrosine phosphorylation and CD95 activation. As sorafenib is promoting the activation of Src family kinases, we reasoned that it is probable that other Src kinases are also phosphorylated in response to sorafenib treatment. Increased FAK signaling has the potential to promote metastatic spread of tumor cells via Src. Signaling by Src kinases is known to facilitate ERBB1 Y845 phosphorylation and we observed this in our system following sorafenib treatment. Phosphorylation of Y845 has been linked to ERBB1-induced tumor cell growth, independent of ERK1/2 and phosphoinositide-3-kinase signaling. low concentrations of sorafenib have been shown to promote MEK1/2 activation via IGF1 receptor signaling, and inhibition of MEK1/2 signaling enhanced sorafenib toxicity. Thus, the practical outcome of sorafenib promoting Src kinase activation is that while this drug acts to suppress tumor growth through Src-dependent activation of CD95, the induction of endoplasmic reticulum stress and inhibition of proangiogenic growth factor receptors; it also has the capacity to promote tumor cell survival and migration through elevated signaling by Src, FAK, ERBB1, IGF1R, and possibly, the ERK1/2 pathway. Additional studies will be required to define the precise nodal enzymes within the sorafenib-induced signaling network that can promote and suppress sorafenib lethality. In conclusion, the present studies provide additional mechanistic information as to how these agents interact and, furthermore, predict that inhibitors of survival signaling receptors, e.g., ERBB1 and IGF1R, which are activated in response to sorafenib exposure, will enhance the antitumor efficacy of this drug combination.We has established long-term and stable relationships with more than 10,000 customers from pharmaceutical and biotech companies, universities and research institutions. We have high quality inhibitors like hdac inhibitor, hdac inhibitors, Taxol & more. We have headquarters in both United States and Europe, and also has 38 distributors worldwide. We provide overnight delivery in North America and Europe.
Related Articles -
Sorafenib, Vorinostat, HDAC inhibitor,
|
